Background/Aims: Whether angiotensin-converting enzyme (ACE) inhibitors or angiotensin
II receptor blockers (ARB) could benefit patients with diabetes and albuminuria remains …

Objective To evaluate the effects of angiotensin converting enzyme (ACE) inhibitors and
angiotensin II receptor antagonists (AIIRAs) on renal outcomes and all cause mortality in …

Background. A recent clinical trial showed harmful renal effects with the combined use of
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin-II receptor blockers (ARB) …

Background/Aims: Limited evidence exists on the choice of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) in diabetic patients with …

Background In contrast to previous studies, recent data questioned the ability of renin–
angiotensin–aldosterone system (RAAS) blockers to delay progression of diabetic …

Background The comparative effectiveness of treatment with angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs), or their combination in people with …

Importance Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor
blockers (ARBs) may have different effects on cardiovascular (CV) events in patients with …

Objective: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) reduce proteinuria in diabetic nephropathy (DN). Some studies have …

During the past decade, the incidence of end-stage renal disease (ESRD) has risen
dramatically, primarily due to an increase in the incidence of diabetes. In patients with …

Diabetic kidney disease is characterized by persistent albuminuria (> 300 mg/dl or> 200
μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive …